The Personalis Mission
Our mission is to help cancer patients by enabling the next generation of personalized immuno-oncology therapeutics and diagnostics through rigorous innovation.

It Starts with Comprehensive Tumor Immunogenomics

Personalis is partnering with pharmaceutical companies to advance the development of more effective cancer immunotherapies by providing highly accurate and comprehensive tumor immunogenomics.
Our ACE ImmunoID Platform combines our augmented exome and transcriptome assays with advanced analytics to support our pharmaceutical partners at all stages of the drug development process; from discovery and translational research studies and clinical trials, to post-approval and commercialization.

Applications for
Biomarker Discovery

Applications for
Personalized Cancer Vaccines

Introducing:

ImmunoID NeXT™

The Universal Cancer Immunogenomics Platform

ImmunoID NeXT is the first platform to provide comprehensive analysis of both a tumor and its microenvironment from a single sample. It consolidates multiple oncology biomarker assays into one – maximizing the biological insights garnered from a single, precious tumor specimen. Traditionally, when samples are limited, researchers must make a difficult decision around which biomarkers to analyze. With ImmunoID NeXT, our partners no longer have to make this decision.

A Single Platform. A Single Sample. Multiple Biomarkers.

Personalis is offering pharmaceutical customers the opportunity to participate in an Early Access Program, ongoing now.
Learn More
Join Us!
  • ICI-IO Combinations Summit, Boston | March 19-21
  • AACR Annual Meeting, Atlanta | March 29-April 3
  • 2019 NeoAG Summit Europe, Amsterdam | April 23-25
  • Advances in Immuno-Oncology Congress Europe, London | May 20-21
  • Rational Combinations 360°, Philadelphia | June 20-21
Learn More

Ready to streamline your precision oncology 
translational and clinical research programs?

Contact Us